Sector News

Oxford given £100m for antibiotic resistance research

January 23, 2021
Energy & Chemical Value Chain

Britain’s Oxford University has received a donation of £100 million (112 million euros, $136 million) to research growing resistance to antibiotics, the university announced on Tuesday.

The sum, from British chemicals multinational Ineos, is one of the largest donations given to Oxford University in its long history.

The funding will be used to launch a new institute to combat the growing phenomenon of antimicrobial resistance (AMR), caused by the increasing exposure of animals and humans to the medicines which treat diseases caused by bacteria.

Increasing antibiotic resistance already causes 1.5 million excess deaths each year, the University of Oxford has said.

By 2050, up to 10 million deaths each year could be caused because antibiotics and other antimicrobial drugs are no longer effective against common diseases.

Oxford’s vice-chancellor Professor Louise Richardson said the coronavirus pandemic had shown the urgent need to deal with the “cataclysmic” threat posed to public health by antibiotic resistance.

“We certainly knew that there was a high potential for another pandemic, we were reminded of that many times, and yet we were caught unprepared,” she said.

“We know that human antibiotics are, with every passing year, becoming fewer and fewer because of the growth of resistance so it’s absolutely imperative that we act, and the impact of being unprepared for the pandemic I think reinforces the importance of acting before it’s too late.”

Ineos chief executive Jim Ratcliffe said collaboration between industry and academia was “now crucial to fight against AMR”.

“We are excited to partner with one of the world’s leading research universities to accelerate progress in tackling this urgent global challenge,” he added.

The discovery of penicillin — the world’s first antibiotic — was made at Oxford and has subsequently saved millions of lives around the world.

In partnership with the British drugs company AstraZeneca, a team at Oxford University also developed one of the first vaccines to protect from Covid-19.

“The vaccines which have been created in record time and which offer light at the end of the tunnel were developed using research conducted long before Covid-19 struck,” said David Sweetnam, an adviser to the Ineos Oxford Institute.

“It’s clear that we must be looking right now for new antibiotics with the same urgency as we have been for vaccines,” he added.

by France24.c0m

Source: france24.com

comments closed

Related News

March 15, 2024

Sasol appoints Antje Gerber as new Chemicals EVP

Energy & Chemical Value Chain

Sasol has appointed Antje Gerber as executive vice president Chemicals and member of the group executive committee, effective April 15, 2024. She will succeed Brad Griffith, who is to retire on June 30, 2024. In her career, Gerber has held executive roles at several major chemicals players including Venator, HB Fuller and Evonik.

March 15, 2024

NOVA Chemicals launches Centre of Excellence for Plastics Circularity

Energy & Chemical Value Chain

Sustainable polyethylene (PE) producer Nova Chemicals has announced the establishment of its Centre of Excellence for Plastics Circularity in Alberta, Canada. The new hub will act as a nexus for industry leaders and Canadian R&D institutions committed to enhancing global sustainable plastics management efforts.

March 15, 2024

A more competitive, self-sufficient and greener region: MOL Group is to achieve carbon neutrality with a smart transition

Energy & Chemical Value Chain

MOL Group updates its long-term strategy announced in 2016 and aims to achieve carbon neutrality by 2050 through smart transition: ensuring sustainability and further strengthening security of supply through innovative technologies. The company will further strengthen its refineries with $150 million in efficiency improvements.

How can we help you?

We're easy to reach